InvestSMART

HeraMED Limited (ASX:HMD)

ALERT: Price-sensitive ASX Announcement for HMD
Current share price for HMD : $0.042 0.003 (7.69%)+
Announcement
Release
14 Jul 2026 8:50AM
Price at Release
$0.039
Full Release
download
Summary
HeraMED Limited, an Australian company, announced the successful completion of Phase 1 of its Digital Pregnancy Journey pilot with Lee Health, a major US healthcare provider. The pilot evaluated the HeraCARE platform as part of a digital-first pregnancy care model, incorporating virtual visits, remote patient monitoring, and other digital tools to reduce in-person visits. The six-month pilot resulted in strong patient adoption and engagement, with 92% virtual adoption and 100% likelihood to recommend. The model demonstrated potential to free up clinic capacity and reduce patient travel burdens. Following positive results, HeraMED and Lee Health are moving towards Phase 2 of the program.
Key Points
  • HeraMED successfully completes Phase 1 pilot with Lee Health.
  • Phase 1 evaluated the HeraCARE platform in a digital-first pregnancy care model.
  • Six-month pilot reduced reliance on in-person visits.
  • 92% virtual adoption and 100% likelihood to recommend.
  • Pilot indicated freeing up 3–5 prenatal appointment slots per patient.
  • HeraMED and Lee Health progressing to Phase 2 of the program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.